We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | NASDAQ:IOVA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 13.88 | 12.35 | 13.87 | 61 | 09:24:30 |
| | ||||||||||||||||||||||||
Title of each class of
securities to be registered |
| |
Amount
to be registered(1) |
| |
Maximum
offering price per share |
| |
Maximum
aggregate offering price |
| |
Amount of
registration fee(2)(3) |
| ||||||||||||
Common stock, par value $0.000041666 per share
|
| | | | 19,475,806 | | | | | $ | 31.00 | | | | | $ | 603,749,986.00 | | | | | $ | 78,366.75 | | |
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||
Public Offering Price
|
| | | $ | 31.00 | | | | | $ | 525,000,004 | | |
Underwriting Discounts and Commissions(1)
|
| | | $ | 1.86 | | | | | $ | 31,500,000 | | |
Offering to Iovance Biotherapeutics, Inc. before expenses
|
| | | $ | 29.14 | | | | | $ | 493,500,004 | | |
| | | | | | | | | | | | | |
| Jefferies | | |
Goldman Sachs & Co. LLC
|
| |
Wells Fargo Securities
|
|
| Baird | | |
H.C. Wainwright & Co.
|
|
| | |
Page
|
| |||
Prospectus Supplement | | | | | | | |
| | | | S-iii | | | |
| | | | S-iv | | | |
| | | | S-1 | | | |
| | | | S-7 | | | |
| | | | S-10 | | | |
| | | | S-11 | | | |
| | | | S-15 | | | |
| | | | S-22 | | | |
| | | | S-22 | | | |
| | | | S-22 | | | |
| | | | S-23 | | | |
Prospectus | | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
EXPERTS | | | | | 26 | | |
| | | | 26 | | | |
| | | | 27 | | |
UNDERWRITER
|
| |
NUMBER OF
SHARES |
| |||
Jefferies LLC
|
| | | | 6,774,194 | | |
Goldman Sachs & Co. LLC
|
| | | | 6,774,194 | | |
Wells Fargo Securities, LLC
|
| | | | 1,693,549 | | |
Oppenheimer & Co. Inc.
|
| | | | 592,742 | | |
Robert W. Baird & Co. Incorporated
|
| | | | 592,741 | | |
H.C. Wainwright & Co., LLC
|
| | | | 508,064 | | |
Total
|
| | | | 16,935,484 | | |
| | | | | | | |
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||||||||||||||
| | |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| ||||||||||||
Public offering price
|
| | | $ | 31.00 | | | | | $ | 31.00 | | | | | $ | 525,000,004 | | | | | $ | 603,749,986 | | |
Underwriting discounts and commissions
paid by us |
| | | $ | 1.86 | | | | | $ | 1.86 | | | | | $ | 31,500,000 | | | | | $ | 36,224,999 | | |
Proceeds to us, before expenses
|
| | | $ | 29.14 | | | | | $ | 29.14 | | | | | $ | 493,500,004 | | | | | $ | 567,524,987 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
1 Year Iovance Biotherapeutics Chart |
1 Month Iovance Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions